Asset Dedication LLC’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-50
Closed -$1.32K 1244
2026
Q1
$1.32K Hold
50
﹤0.01% 1000
2025
Q4
$1.45K Hold
50
﹤0.01% 1025
2025
Q3
$1.39K Hold
50
﹤0.01% 1047
2025
Q2
$1.22K Hold
50
﹤0.01% 1072
2025
Q1
$1.04K Hold
50
﹤0.01% 1018
2024
Q4
$1.18K Hold
50
﹤0.01% 1008
2024
Q3
$1.28K Sell
50
-124
-71% -$3.16K ﹤0.01% 1044
2024
Q2
$4.09K Hold
174
﹤0.01% 962
2024
Q1
$5K Hold
174
﹤0.01% 771
2023
Q4
$6K Hold
174
﹤0.01% 749
2023
Q3
$4K Hold
174
﹤0.01% 806
2023
Q2
$6K Hold
174
﹤0.01% 729
2023
Q1
$6K Hold
174
﹤0.01% 711
2022
Q4
$5K Hold
174
﹤0.01% 741
2022
Q3
$6K Hold
174
﹤0.01% 683
2022
Q2
$6K Hold
174
﹤0.01% 376
2022
Q1
$8K Hold
174
﹤0.01% 677
2021
Q4
$11K Sell
174
-350
-67% -$24.2K ﹤0.01% 629
2021
Q3
$38K Buy
524
+179
+52% +$15K 0.01% 461
2021
Q2
$31K Buy
345
+50
+17% +$4.25K ﹤0.01% 468
2021
Q1
$26K Buy
295
+245
+490% +$24.3K 0.01% 403
2020
Q4
$5K Buy
+50
New +$3.98K ﹤0.01% 624

Other funds holding ARKG

Asset Dedication LLC's ARKG Position: Q2 2026 in Review

Asset Dedication LLC sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2026, closing a stake of 50 shares — an estimated $1.32K sold.

Asset Dedication LLC first reported a position in ARKG in Q4 2020 and held it in 22 quarters. The position peaked at $38K in Q3 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Asset Dedication LLC reported no remaining ARK Genomic Revolution ETF position as of Q2 2026 after selling out during the quarter.
  • Asset Dedication LLC sold 50 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $1.32K.
  • Asset Dedication LLC first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 22 quarters.
  • Asset Dedication LLC's ARK Genomic Revolution ETF position peaked at $38K in Q3 2021.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Asset Dedication LLC's 13F filing for Q2 2026, filed 30 Jul 2026.